Johnson & Johnson (JNJ) Retained Earnings (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Retained Earnings came in at -$14.8 billion in Q1 2026, down 109.12% year-on-year from $162.6 billion in Q1 2025, and down 108.78% quarter-over-quarter from $169.0 billion in Q4 2025.
Johnson & Johnson (JNJ) Retained Earnings (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Retained Earnings across 18 years of filings, most recently posting -$14.8 billion for Q1 2026.
- Retained Earnings for Q1 2026 came in at -$14.8 billion, down 109.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$14.8 billion (down 109.12% YoY), and the FY2025 annual result was $169.0 billion, up 8.46% from the prior year.
- Retained Earnings came in at -$14.8 billion for Q1 2026 at Johnson & Johnson, down from $169.0 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $169.0 billion in Q4 2025 to a low of -$15.3 billion in Q4 2022.
- The 5-year median for Retained Earnings is $56.6 billion (2022), against an average of $65.4 billion.
- Across the five-year window, Retained Earnings tumbled 111.52% in 2022 and soared 1343.64% in 2024, its largest moves.
- Johnson & Johnson's Retained Earnings stood at -$15.3 billion in 2022, then increased by 18.08% to -$12.5 billion in 2023, then jumped by 1343.64% to $155.8 billion in 2024, then advanced by 8.46% to $169.0 billion in 2025, then slumped by 108.78% to -$14.8 billion in 2026.
- The last three Retained Earnings figures came in at -$14.8 billion (Q1 2026), $169.0 billion (Q4 2025), and -$15.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -14.83 Bn |
| Dec 28, 2025 | 168.98 Bn |
| Sep 28, 2025 | -15.24 Bn |
| Jun 29, 2025 | -14.31 Bn |
| Mar 30, 2025 | 162.64 Bn |
| Dec 29, 2024 | 155.79 Bn |
| Sep 29, 2024 | -12.52 Bn |
| Jun 30, 2024 | -11.25 Bn |
| Mar 31, 2024 | 153.38 Bn |
| Dec 31, 2023 | -12.53 Bn |
| Oct 1, 2023 | 152.54 Bn |
| Jul 2, 2023 | 129.38 Bn |
| Apr 2, 2023 | 124.56 Bn |
| Jan 1, 2023 | 128.35 Bn |
| Oct 2, 2022 | -15.29 Bn |
| Jul 3, 2022 | -13.84 Bn |
| Apr 3, 2022 | 124.38 Bn |
| Jan 2, 2022 | -13.06 Bn |
| Oct 3, 2021 | -15.42 Bn |
| Jul 4, 2021 | 120.15 Bn |